Company: RNAC
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001453687-25-000085
Chunk: 36

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
 provided financing to Cyrus other than the amount contractually required by the Series B Preferred Stock Purchase Agreement.

13

6. Net Loss Per Share Allocable to Common Stockholders

The Company reported a net loss for the three months ended March 31, 2025 and 2024. The following table sets forth the computation of basic and diluted net loss per share allocable to common stockholders for the three months ended March 31, 2025 and 2024 (in thousands, except share and per-share data): Three Months EndedMarch 31, 20252024Numerator:     Net loss$(17,710)$(56,824)Denominator:     Weighted-average common shares outstanding - basic and diluted25,902,650 5,414,020 Net loss per share:     Basic and diluted$(0.68)$(10.50)The following table represents the potential dilutive shares of common stock excluded from the computation of the diluted net loss per share allocable to common stockholders for all periods presented, as the effect would have been anti-dilutive:  Three Months EndedMarch 31, 20252024Common stock options and restricted stock units3,047,628 1,811,636 Warrants to purchase common stock692,523 975,132 Series A Preferred Stock4,026,346 17,808,670 Series A Preferred Stock options— 470,403 Series B Preferred Stock437,927 — Total8,204,424 21,065,841 

7. Fair Value Measurements

The following tables present the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2025 and December 31, 2024 (in thousands):March 31, 2025TotalLevel 1Level 2Level 3Assets:     Money market funds (included in cash equivalents)$39,509 $39,509 $— $— Total assets$39,509 $39,509 $— $— Liabilities:     Warrant liabilities$2,018 $— $— $2,018      Contingent value right liability$387,400 $— $— $387,400 Total liabilities$389,418 $— $— $389,418  December 31, 2024TotalLevel 1